Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-337P is a **pseudogene** derived from the U6 small nuclear RNA (snRNA) family. U6 snRNA is a highly conserved component of the major spliceosomal machinery, essential for pre-mRNA splicing in eukaryotes[3][1]. Unlike functional U6 genes, RNU6-337P does not produce an active snRNA molecule. Pseudogenes such as RNU6-337P are often transcriptionally silent or non-functional, but emerging evidence indicates that some pseudogenes can participate in gene regulation by acting as molecular decoys, endogenous siRNAs, or regulatory long noncoding RNAs[4]. There is no evidence that RNU6-337P has a direct biological function, nor is it considered a therapeutic target, receptor, enzyme, or transporter. Its primary relevance is in genomics, where pseudogenes are used in studies of genome evolution, genetic diversity, and potential biomarker discovery. The presence and expression of pseudogenes in various diseases, including cancer, are under investigation, with some pseudogenes implicated in disease-specific expression profiles or regulatory mechanisms[4]. **Note:** - RNU6-337P should not be confused with functional U6 small nuclear RNA or its variants; it is classified specifically as a **processed pseudogene**, and not as a receptor, enzyme, nor a direct target for drugs or therapeutic modulation[2][3][4]. - No known drugs, biomarkers, or safety concerns are associated with RNU6-337P. - Its aliases include alternative names reflecting its derivation from the U6 small nuclear RNA gene family and pseudogene status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 337, pseudogene (RNU6-337P).